Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Alshreef A, Flight L, Pennington R, Hounsome B, Lever E, Metry A, Poku E, Yang Y, Harding SP, Lotery A, Chakravarthy U, Brazier J. Hykin P, et al. Among authors: poku e. Health Technol Assess. 2021 Jun;25(38):1-196. doi: 10.3310/hta25380. Health Technol Assess. 2021. PMID: 34132192 Free PMC article. Clinical Trial.
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Yang Y, Lotery A, Williams M, Brazier J. Pennington B, et al. Among authors: poku e. Pharmacoeconomics. 2021 Aug;39(8):913-927. doi: 10.1007/s40273-021-01026-5. Epub 2021 Apr 26. Pharmacoeconomics. 2021. PMID: 33900585 Free PMC article. Clinical Trial.
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Yang Y, Lotery A, Williams M, Brazier J. Pennington B, et al. Among authors: poku e. Pharmacoeconomics. 2021 Sep;39(9):1099. doi: 10.1007/s40273-021-01057-y. Pharmacoeconomics. 2021. PMID: 34148190 Free PMC article. No abstract available.
Dexamethasone implant for non-infectious uveitis: is it cost-effective?
Squires H, Bermejo I, Poku EN, Cooper K, Stevens J, Hamilton J, Wong R, Denniston AK, Pearce I, Quhill FM. Squires H, et al. Br J Ophthalmol. 2019 Nov;103(11):1639-1644. doi: 10.1136/bjophthalmol-2018-312765. Epub 2019 Feb 11. Br J Ophthalmol. 2019. PMID: 30745307 Free article.
64 results